Gyre Therapeutics, Inc. Excess Tax Benefit from Share-based Compensation, Financing Activities
Gyre Therapeutics, Inc. (GYRE) reported Excess Tax Benefit from Share-based Compensation, Financing Activities of $3.41 million for the 12-month period ending 2014-12-31, per its 10-K filed 2015-03-16.
Discontinued › Notes › Compensation Related Costs
us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities · last filed 2015-07-31
- Gyre Therapeutics, Inc. excess tax benefit from share-based compensation, financing activities for the quarter ending 2014-12-31 was $0.00.
- Gyre Therapeutics, Inc. excess tax benefit from share-based compensation, financing activities for the quarter ending 2014-09-30 was $0.00.
- Gyre Therapeutics, Inc. excess tax benefit from share-based compensation, financing activities for the quarter ending 2014-06-30 was $0.00.
- Gyre Therapeutics, Inc. excess tax benefit from share-based compensation, financing activities for the quarter ending 2014-03-31 was $3.41M.
- Gyre Therapeutics, Inc. excess tax benefit from share-based compensation, financing activities for fiscal 2014 was $3.41M.
- Gyre Therapeutics, Inc. excess tax benefit from share-based compensation, financing activities for fiscal 2010 was $3.50M, a 8443.90% increase from fiscal 2009.
- Gyre Therapeutics, Inc. excess tax benefit from share-based compensation, financing activities for fiscal 2009 was $41.00K.
| Period end | Excess Tax Benefit from Share-based Compensation, Financing Activities 3 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 6 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 9 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 12 month |
|---|---|---|---|---|
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | $0.00 derived: sum of 2 quarters · filed 2015-03-16 | $0.00 derived: sum of 3 quarters · filed 2015-07-31 | $3.41M 10-K · filed 2015-03-16 |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $0.00 derived: sum of 2 quarters · filed 2015-07-31 | $3.41M 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-31 | $3.41M 10-Q · filed 2015-07-31 | ||
| 2014-03-31 | $3.41M 10-Q · filed 2015-05-07 | |||
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $0.00 10-Q · filed 2014-11-06 | ||
| 2013-06-30 | $0.00 10-Q · filed 2014-08-07 | |||
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-03 | $0.00 10-Q · filed 2011-11-03 | ||
| 2011-06-30 | $0.00 10-Q · filed 2011-08-09 | |||
| 2010-12-31 | $1.23M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-15 | $1.39M derived: sum of 2 quarters · filed 2013-03-15 | $3.50M 10-K · filed 2013-03-15 | |
| 2010-09-30 | $160.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-03 | $2.28M 10-Q · filed 2011-11-03 | ||
| 2010-06-30 | $2.12M 10-Q · filed 2011-08-09 | |||
| 2009-12-31 | $41.00K 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |